Company: STAA
Filing Date: 2025-09-29
Form Type: DFAN14A
Source: 0001213900-25-093211
Chunk: 19

Company: STAAR SURGICAL CO
Filing Date: 2025-09-29
Form: DFAN14A
Chunk 19
---
 challenges in the markets Staar serves. Staar
is heavily exposed to China, which faces significant economic uncertainty and where sales trends have been declining despite actions taken
by the company. Notably, Staar’s common stock closed at $18.49 per share on the trading day prior to the announcement of the Alcon
agreement.

The merger agreement includes provisions that are highly
favorable to Staar stockholders and were extensively negotiated by the company to further its value-maximizing objective.

We look forward to engaging with our stockholders on the
merits of the Alcon merger and why the Staar board of directors unanimously believes it is in the best interest of all Staar stockholders.”

Exhibit 6

STAAR Surgical’s largest shareholder opposes Alcon takeover

Amid plummeting revenues, last month STAAR Surgical conceded that Alcon’s
$1.5bn proposal to acquire the company represented “the best path forward” for its shareholders.

Ross Law | September 2, 2025

STAAR Surgical’s largest shareholder has said it plans to vote
against Alcon’s proposed $1.5bn takeover of the ailing eye specialist.

Broadwood Partners, which owns 27.3% of STAAR’s common shares,
said the transaction, announced last month, suffered from “multiple process and valuation deficiencies”.

The investment firm expressed disappointment over the actions of STAAR’s
board, claiming it had failed to pursue an “adequate” sale process. According to Broadwood, STAAR’s board also displayed
“intransigence” in relation to Broadwood’s books and record demand, stating it had received no documents since making
the request more than three weeks ago.

STAAR’s Q1 2025 financials revealed a 45% decline in sales to
$42.6m, down from $77.4m in Q1 2024, with the US-based company chiefly attributing the sharp decline to weakened demand in China and additional
headwinds due to government initiatives in the country affecting device procurement.

Broadwood’s primary point of contention relates to the proposed
financial terms of Alcon’s acquisition. The shareholder pointed out that Alcon previously offered $55 per share for STAAR when it
moved to acquire the company in October 2024 – a price “far above” the current offer of $28 per share.

Alcon subsequently pulled back from its initial offer after learning
that STAAR was facing inventory management challenges, with the revelation giving